Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
Clinical trial NCT03412643 · UNKNOWN
Trial details
- NCT number
- NCT03412643
- Sponsor
- NSABP Foundation Inc
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-05-14
- Primary completion
- 2023-10-30
- Enrollment
- 64
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.